ArticleInternational journal of cancer2019
Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
Open access · greenAbstract read
In one paragraph
Article in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Mapping and visualization of global research progress on deubiquitinases in ovarian cancer: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Ovarian Cancer: New Insight and Future Perspectives.Molecular biotechnology · 2026Review
- Analysis of ovarian cancer burden among reproductive-aged women and its association with the socio-demographic index from 1990 to 2021.World journal of surgical oncology · 2026Article
- Study protocol: analysis of gene expression profiles in peripheral blood and tumor tissue of Colombian patients diagnosed with epithelial ovarian cancer.Frontiers in oncology · 2026Article
- NETs in ovarian cancer progression: innovative nanoparticle-based therapeutic strategies.European journal of medical research · 2025Review
- Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Association between dietary vitamin intake and all-cause mortality in ovarian cancer patients: a prospective cohort study.Frontiers in nutrition · 2025Article
- Article
- Association of smoking, alcohol, and coffee consumption with the risk of ovarian cancer and prognosis: a mendelian randomization study.BMC cancer · 2023Article
- Lifetime Exposure to Cigarette Smoke and Risk of Ovarian Cancer by T-cell Tumor Immune Infiltration.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Predictors of residual disease after debulking surgery in advanced stage ovarian cancer.Frontiers in oncology · 2023Article
- Associations of Dietary Intakes with Gynecological Cancers: Findings from a Cross-Sectional Study.Nutrients · 2022Article
- LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter.Molecular medicine (Cambridge, Mass.) · 2022Article
- A Multi-State Survival Model for Time to Breast Cancer Mortality among a Cohort of Initially Disease-Free Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).International journal of epidemiology · 2022Article
- Metabolic risk factors of ovarian cancer: a review.JBRA assisted reproduction · 2022Review
- Article
- Prediagnosis and postdiagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.International journal of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 20 institutions in 16 countries.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-1426-8505
Elizabeth M PooleChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Nicolas A WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
Britton TrabertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
Emily WhiteFred Hutchinson Cancer Research Center, Seattle, WA.
Alan A ArslanNew York University School of Medicine, New York, NY.
Alpa V PatelEpidemiology Research Program, American Cancer Society, Atlanta, GA.
V Wendy SetiawanUniversity of Southern California, Los Angeles, CA.
Kala VisvanathanJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Hans-Olov AdamiDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Amanda BlackDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
Leslie BernsteinCity of Hope, Duarte, CA.
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
Julie BuringDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Tess V ClendenenNew York University School of Medicine, New York, NY.ORCID 0000-0003-4170-6977
Agnès FournierCESP "Health across Generations," INSERM, Univ Paris-Sud, UVSQ, Univ Paris-Saclay, Villejuif, France.
Gary FraserLoma Linda University, Loma Linda, CA.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta, GA.
Mia M GaudetEpidemiology Research Program, American Cancer Society, Atlanta, GA.ORCID 0000-0002-6429-4007
Graham G GilesCancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
Inger T GramDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Patricia HartgeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
Judith Hoffman-BoltonJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Annika IdahlDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-3751-3929
Victoria A KirshDivision of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Synnove KnutsenLoma Linda University, Loma Linda, CA.
Woon-Puay KohHealth Services and Systems Research, Duke-NUS Medical School Singapore, Singapore.
James V LaceyCity of Hope, Duarte, CA.
I-Min LeeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Eva LundinDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Melissa A MerrittCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
Roger L MilneCancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
N Charlotte Onland-MoretJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Ulrike PetersFred Hutchinson Cancer Research Center, Seattle, WA.
Jenny N PoynterDepartment of Pediatrics, University of Minnesota, Minneapolis, MN.ORCID 0000-0002-8460-3938
Sabina RinaldiInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-6846-1204
Kim RobienDepartment of Exercise and Nutrition Sciences, Milken Institute School of Public Health, George Washington University, Washington, D.C.
Thomas RohanDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Maria-José SánchezEscuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Catherine SchairerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.ORCID 0000-0001-7671-4972
Leo J SchoutenGROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0003-3361-7560
Anne TjonnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Mary K TownsendDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Piet A van den BrandtGROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0001-8781-8099
Paolo VineisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, United Kingdom.
Lynne WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Hannah P YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
Anne Zeleniuch-JacquotteNew York University School of Medicine, New York, NY.
Shelley S TworogerChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
National Cancer Institute · USBrigham and Women's Hospital · USAmerican Cancer Society · USNew York University · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZACity of Hope · USGerman Cancer Research Center · DEJohns Hopkins University · USLoma Linda University · USMaastricht University · NLThe University of Melbourne · AUUmeå University · SEUniversity of Hawaiʻi at Mānoa · USAlbert Einstein College of Medicine · USCentre international de recherche sur le cancer · FRDanish Cancer Society · DKDuke-NUS Medical School · SGHarvard University · USInserm · FRItalian institute for Genomic Medicine · IT
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, TAMIMI, RULLA M · 2000 to 2019
$77.8MThe Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5MUniversity of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Pallav Pokhrel · 1996 to 2026
$56.2MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MPLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9MCALIFORNIA TEACHERS STUDYR01CA077398 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERNSTEIN, LESLIE · 1998 to 2014
$29.7MWomen's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2MRESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1MLife Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4MLong Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3MOil and Gas as Drivers of Climate Change and Health: Developing unique resources to investigate multi-level and diverse effects of exposure to oil and gas wellsU01CA199277 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LACEY, JAMES V, MARTINEZ, MARIA ELENA · 2015 to 2024
$20.7MCancer Research UK 14136Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCI NIH HHS K05 CA154337NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA039742NCI NIH HHS R01 CA047988NCI NIH HHS R01 CA067262NCI NIH HHS R01 CA077398NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA176726NCI NIH HHS U01 CA182876NCI NIH HHS U01 CA182913NCI NIH HHS U01 CA199277NCI NIH HHS UM1 CA164917NCI NIH HHS UM1 CA164973NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182876NCI NIH HHS UM1 CA182934NCI NIH HHS UM1 CA186107NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS RC1 HL099355NIEHS NIH HHS P30 ES000260NIMHD NIH HHS U54 MD007601World Health Organization 001
Abstract
Ovarian cancer risk factors differ by histotype; however, within subtype, there is substantial variability in outcomes. We hypothesized that risk factor profiles may influence tumor aggressiveness, defined by time between diagnosis and death, independent of histology. Among 1.3 million women from 21 prospective cohorts, 4,584 invasive epithelial ovarian cancers were identified and classified as highly aggressive (death in <1 year, n = 864), very aggressive (death in 1 to < 3 years, n = 1,390), moderately aggressive (death in 3 to < 5 years, n = 639), and less aggressive (lived 5+ years, n = 1,691). Using competing risks Cox proportional hazards regression, we assessed heterogeneity of associations by tumor aggressiveness for all cases and among serous and endometrioid/clear cell tumors. Associations between parity (p
Indexed as
AgedBody Mass IndexCarcinoma, Ovarian EpithelialCohort StudiesFemaleHumansMiddle AgedNeoplasm InvasivenessOvarian NeoplasmsParityPregnancyProportional Hazards ModelsProspective StudiesRisk FactorsSmokingaggressivenessovarian cancerprospective cohortrisk factorssubtypes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.